These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 15330747)
1. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Eisenstein BI Expert Opin Investig Drugs; 2004 Sep; 13(9):1159-69. PubMed ID: 15330747 [TBL] [Abstract][Full Text] [Related]
2. Daptomycin: a new drug class for the treatment of Gram-positive infections. Alder JD Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781 [TBL] [Abstract][Full Text] [Related]
4. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. Steenbergen JN; Alder J; Thorne GM; Tally FP J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Carpenter CF; Chambers HF Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832 [TBL] [Abstract][Full Text] [Related]
6. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Kanafani ZA; Corey GR Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833 [TBL] [Abstract][Full Text] [Related]
7. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Johnson A Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638 [TBL] [Abstract][Full Text] [Related]
8. Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Kern WV Int J Clin Pract; 2006 Mar; 60(3):370-8. PubMed ID: 16494659 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
10. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Vilhena C; Bettencourt A Mini Rev Med Chem; 2012 Mar; 12(3):202-9. PubMed ID: 22356191 [TBL] [Abstract][Full Text] [Related]
11. Daptomycin: a new treatment for insidious infections due to gram-positive pathogens. Cottagnoud P Swiss Med Wkly; 2008 Feb; 138(7-8):93-9. PubMed ID: 18293118 [TBL] [Abstract][Full Text] [Related]
13. Management of cSSTIs: the role of daptomycin. Garau J Curr Med Res Opin; 2006 Nov; 22(11):2079-87. PubMed ID: 17076967 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Hair PI; Keam SJ Drugs; 2007; 67(10):1483-512. PubMed ID: 17600394 [TBL] [Abstract][Full Text] [Related]
15. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Baltz RH; Miao V; Wrigley SK Nat Prod Rep; 2005 Dec; 22(6):717-41. PubMed ID: 16311632 [TBL] [Abstract][Full Text] [Related]
16. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient]. Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665 [TBL] [Abstract][Full Text] [Related]
17. Daptomycin, a lipopeptide antibiotic in clinical practice. Weis F; Beiras-Fernandez A; Schelling G Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036 [TBL] [Abstract][Full Text] [Related]
19. Daptomycin. Enoch DA; Bygott JM; Daly ML; Karas JA J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567 [TBL] [Abstract][Full Text] [Related]
20. Daptomycin in bone and joint infections: a review of the literature. Rice DA; Mendez-Vigo L Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]